Answers are grounded in this paper and cite their sources.
Background & Aims The optimal antiviral agent for chronic hepatitis B (CHB) patients at risk for osteoporosis remains debated. This study aimed to compare the incidence of osteoporosis and osteoporotic fractures between tenofovir disoproxil fumarate (TDF) and entecavir (ETV) using a nationwide cohort in South Korea. Method We analyzed 40,404 CHB patients treated with either TDF (n = 23,779) or ETV (n = 16,625). The risk of osteoporosis and osteoporotic fractures was evaluated using Cox proportional hazards models, incidence rate ratios (IRRs), and Kaplan–Meier survival analysis. To adjust for baseline differences, inverse probability of treatment weighting (IPTW) was applied. Result Over a mean follow-up of 50.8 months, osteoporosis occurred in 1,712 TDF users and 1,094 ETV users. The incidence rate of osteoporosis was significantly higher in the TDF group (IRR 1.30, 95% CI: 1.23–1.37; p < 0.001). Multivariate Cox regression also confirmed increased osteoporosis risk with TDF (HR 1.328, 95% CI: 1.258–1.401; p < 0.001), while fracture incidence was not significantly different (HR 1.027, 95% CI: 0.939 – 1.122, p = 0.569). In patients aged ≥60 years, the TDF group had significantly higher risk of both osteoporosis (HR 1.347, 95% CI: 1.224–1.484; p < 0.001) and fractures (HR 1.213, 95% CI: 1.051–1.403; p = 0.009), with divergence in Kaplan–Meier curves evident after 1 and 3 years of treatment, respectively. Conclusion Long-term use of TDF is significantly associated with an increased risk of osteoporosis and fractures, especially in patients over the age of 60. These findings support the need for proactive bone health surveillance in CHB patients receiving long-term TDF therapy. Impact and implications Our study highlights the need for careful antiviral selection in CHB patients aged 60 and older due to the increased risk of osteoporosis and fractures with long-term TDF use. We recommend using ETV or TAF as the preferred therapies for fracture high-risk group. Early intervention is essential, as fracture incidence tends to rise after 2-3 years of TDF therapy, making regular bone mineral density (BMD) monitoring critical for these patients.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: